Cargando…

Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea

BACKGROUND: Atypical femoral fracture (AFF) has been high-lightened, because it was associated with the long-term use of bisphosphonate. Comparing western countries, the incidence rate of AFF was unclear in East Asian patients. Our purposes were to estimate the incidence rate of radiologically defin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Young-Kyun, Ahn, Soyeon, Kim, Kyoung Min, Suh, Chang Suk, Koo, Kyung-Hoi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773851/
https://www.ncbi.nlm.nih.gov/pubmed/29349947
http://dx.doi.org/10.3346/jkms.2018.33.e38
_version_ 1783293649138745344
author Lee, Young-Kyun
Ahn, Soyeon
Kim, Kyoung Min
Suh, Chang Suk
Koo, Kyung-Hoi
author_facet Lee, Young-Kyun
Ahn, Soyeon
Kim, Kyoung Min
Suh, Chang Suk
Koo, Kyung-Hoi
author_sort Lee, Young-Kyun
collection PubMed
description BACKGROUND: Atypical femoral fracture (AFF) has been high-lightened, because it was associated with the long-term use of bisphosphonate. Comparing western countries, the incidence rate of AFF was unclear in East Asian patients. Our purposes were to estimate the incidence rate of radiologically defined AFF in Korea, and to determine the association between occurrence of AFF and long-term use of bisphosphonate. METHODS: We conducted a hospital-based, retrospective cohort study in patients aged ≥ 45 years, who took bisphosphonate. The occurrence of AFF was estimated by using incidence rate, and the age-adjusted incidence rate to U.S. 2010 Census data. The association between occurrence of AFF and the duration of bisphosphonate use was examined. The cumulative probability of AFF was plotted per each duration of bisphosphonate use. RESULTS: Among 10,338 individuals who took bisphosphonate, 13 patients with AFF following use of bisphosphonate were identified. The incidence rate was 85.9/100,000 person-years (95% confidence interval [CI], 50.2–146.9), and age-adjusted incidence rate was 72.7/100,000 person-years (95% CI, 29.1–175.8). In Poisson regression analysis, higher body mass index (BMI) was associated with an increased risk of AFF (relative risk, 1.2; 95% CI, 1.004–1.359). The cumulative probability of AFF increased abruptly when the duration of bisphosphonate use was 4 years or more. CONCLUSION: Among Korean patients, the incidence rate of AFF was on a par with those of western countries, and this can provide basic information to conduct further studies by evaluating risk and benefit of continuing bisphosphonate.
format Online
Article
Text
id pubmed-5773851
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-57738512018-01-29 Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea Lee, Young-Kyun Ahn, Soyeon Kim, Kyoung Min Suh, Chang Suk Koo, Kyung-Hoi J Korean Med Sci Original Article BACKGROUND: Atypical femoral fracture (AFF) has been high-lightened, because it was associated with the long-term use of bisphosphonate. Comparing western countries, the incidence rate of AFF was unclear in East Asian patients. Our purposes were to estimate the incidence rate of radiologically defined AFF in Korea, and to determine the association between occurrence of AFF and long-term use of bisphosphonate. METHODS: We conducted a hospital-based, retrospective cohort study in patients aged ≥ 45 years, who took bisphosphonate. The occurrence of AFF was estimated by using incidence rate, and the age-adjusted incidence rate to U.S. 2010 Census data. The association between occurrence of AFF and the duration of bisphosphonate use was examined. The cumulative probability of AFF was plotted per each duration of bisphosphonate use. RESULTS: Among 10,338 individuals who took bisphosphonate, 13 patients with AFF following use of bisphosphonate were identified. The incidence rate was 85.9/100,000 person-years (95% confidence interval [CI], 50.2–146.9), and age-adjusted incidence rate was 72.7/100,000 person-years (95% CI, 29.1–175.8). In Poisson regression analysis, higher body mass index (BMI) was associated with an increased risk of AFF (relative risk, 1.2; 95% CI, 1.004–1.359). The cumulative probability of AFF increased abruptly when the duration of bisphosphonate use was 4 years or more. CONCLUSION: Among Korean patients, the incidence rate of AFF was on a par with those of western countries, and this can provide basic information to conduct further studies by evaluating risk and benefit of continuing bisphosphonate. The Korean Academy of Medical Sciences 2018-01-05 /pmc/articles/PMC5773851/ /pubmed/29349947 http://dx.doi.org/10.3346/jkms.2018.33.e38 Text en © 2018 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Young-Kyun
Ahn, Soyeon
Kim, Kyoung Min
Suh, Chang Suk
Koo, Kyung-Hoi
Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea
title Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea
title_full Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea
title_fullStr Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea
title_full_unstemmed Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea
title_short Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea
title_sort incidence rate of atypical femoral fracture after bisphosphonates treatment in korea
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773851/
https://www.ncbi.nlm.nih.gov/pubmed/29349947
http://dx.doi.org/10.3346/jkms.2018.33.e38
work_keys_str_mv AT leeyoungkyun incidencerateofatypicalfemoralfractureafterbisphosphonatestreatmentinkorea
AT ahnsoyeon incidencerateofatypicalfemoralfractureafterbisphosphonatestreatmentinkorea
AT kimkyoungmin incidencerateofatypicalfemoralfractureafterbisphosphonatestreatmentinkorea
AT suhchangsuk incidencerateofatypicalfemoralfractureafterbisphosphonatestreatmentinkorea
AT kookyunghoi incidencerateofatypicalfemoralfractureafterbisphosphonatestreatmentinkorea